- Report
- November 2021
Japan, United States, ... Japan, United States, Europe, Global
From €22533EUR$24,500USD£19,068GBP
- Report
- November 2021
Canada, Mexico, North America Canada, Mexico, North America
From €8737EUR$9,500USD£7,394GBP
- Report
- November 2021
Middle East
From €8737EUR$9,500USD£7,394GBP
- Report
- November 2021
Latin America
From €13336EUR$14,500USD£11,285GBP
- Report
- November 2021
Europe
From €22533EUR$24,500USD£19,068GBP
- Report
- November 2021
Asia Pacific
From €13336EUR$14,500USD£11,285GBP
- Report
- November 2021
Global
From €31730EUR$34,500USD£26,851GBP
The Hemostasis Drug market is a subset of the Hematological Drugs market, which focuses on drugs used to treat and prevent bleeding disorders. Hemostasis drugs are used to stop or reduce bleeding, and can be used to treat conditions such as hemophilia, von Willebrand disease, and thrombocytopenia. These drugs can be administered orally, intravenously, or topically, depending on the condition being treated. Commonly used hemostasis drugs include antifibrinolytics, antithrombotics, and factor concentrates.
The Hemostasis Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, CSL Behring, Grifols, and Shire. Show Less Read more